Free Newsletter
Genzyme re-ups and beefs up business with Hospira for fill/finish ops
Genzyme will have Hospira conduct the final steps of manufacturing for a growing list of drugs under a new supply agreement. Hospira will provide fill/finish services for Cerezyme, Fabrazyme, Thyrogen and Myozyme, as it has been according to a previous agreement, as well as Lumizyme, Thymoglobulin, Campath and products in development. Article
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: